200 related articles for article (PubMed ID: 11555379)
21. Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.
Fan X; Liu Y; Liang Z; Wang S; Yang J; Wu A
Pathol Oncol Res; 2022; 28():1610280. PubMed ID: 35515016
[No Abstract] [Full Text] [Related]
22. Diagnostic value of soluble receptor-binding cancer antigen expressed on SiSo cells and carcinoembryonic antigen in differentiating malignant from benign pleural effusion.
Dong J; Sun G; Zhu H
Tumour Biol; 2016 Mar; 37(3):3257-64. PubMed ID: 26438059
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer.
Sharma SK; Bhat S; Chandel V; Sharma M; Sharma P; Gupta S; Sharma S; Bhat AA
J Carcinog; 2015; 14():7. PubMed ID: 26900349
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion.
Han HS; Yun J; Lim SN; Han JH; Lee KH; Kim ST; Kang MH; Son SM; Lee YM; Choi SY; Yun SJ; Kim WJ; Lee OJ
Int J Cancer; 2013 Aug; 133(3):645-52. PubMed ID: 23354517
[TBL] [Abstract][Full Text] [Related]
25. [The value of B7-H4 and carcinoembryonic antigen in diagnosing the benign and malignant pleural effusion].
Wei F; Wei Y; Li LF; Li GL; Wang GJ
Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):524-527. PubMed ID: 28728299
[No Abstract] [Full Text] [Related]
26. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio).
Verma A; Abisheganaden J; Light RW
Lung; 2016 Feb; 194(1):147-53. PubMed ID: 26678281
[TBL] [Abstract][Full Text] [Related]
27. [Tumor markers in pleural effusion of patients with lung cancer and patients with tuberculous pleurisy].
Tada A; Kawai H; Matsumoto H; Kimura G; Okada C; Soda R; Takahashi K
Nihon Kokyuki Gakkai Zasshi; 2002 Feb; 40(2):106-12. PubMed ID: 11974864
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic value of tumour markers in pleural effusions.
Volarić D; Flego V; Žauhar G; Bulat-Kardum L
Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801
[TBL] [Abstract][Full Text] [Related]
29. [Diagnostic significance of combining telomerase activity with CYFRA21-1 level in differentiating malignant pleural effusion caused by lung cancer from benign pleural effusion].
Li H; Fu J; Xiu Y; Zhou Q
Zhongguo Fei Ai Za Zhi; 2010 Jun; 13(6):652-4. PubMed ID: 20681457
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of serum and pleural levels of the tumor markers CEA, CYFRA21-1 and CA 15-3 in patients with pleural effusion.
Wagner IC; Guimarães MJ; da Silva LK; de Melo FM; Muniz MT
J Bras Pneumol; 2007; 33(2):185-91. PubMed ID: 17724538
[TBL] [Abstract][Full Text] [Related]
31. Pleural fluid cell-free DNA in parapneumonic pleural effusion.
Santotoribio JD; Cabrera-Alarcón JL; Batalha-Caetano P; Macher HC; Guerrero JM
Clin Biochem; 2015 Oct; 48(15):1003-5. PubMed ID: 26234638
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic performance of CD66c in lung adenocarcinoma-associated malignant pleural effusion: comparison with CEA, CA 19-9, and CYFRA 21-1.
Son SM; Han HS; An JY; Choe KH; Lee KM; Lee KH; Kim SS; Lee YM; Lee HC; Song HG; Lee OJ
Pathology; 2015 Feb; 47(2):123-9. PubMed ID: 25551300
[TBL] [Abstract][Full Text] [Related]
33. Pleural interleukin-1 beta in differentiating transudates and exudates: comparative analysis with other biochemical parameters.
Alexandrakis MG; Kyriakou D; Alexandraki R; Pappa KA; Antonakis N; Bouros D
Respiration; 2002; 69(3):201-6. PubMed ID: 12097761
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis.
Yang Y; Liu YL; Shi HZ
Respiration; 2017; 94(1):62-69. PubMed ID: 28427079
[TBL] [Abstract][Full Text] [Related]
35. Procalcitonin as a diagnostic marker in differentiating parapneumonic effusion from tuberculous pleurisy or malignant effusion.
Lee SH; Lee EJ; Min KH; Hur GY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Lee SY
Clin Biochem; 2013 Oct; 46(15):1484-8. PubMed ID: 23570862
[TBL] [Abstract][Full Text] [Related]
36. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H; Ko Y; Lee CY
BMC Cancer; 2020 Aug; 20(1):825. PubMed ID: 32867726
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
38. Is the pleural fluid transudate or exudate? A revisit of the diagnostic criteria.
Joseph J; Badrinath P; Basran GS; Sahn SA
Thorax; 2001 Nov; 56(11):867-70. PubMed ID: 11641512
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of pro-inflammatory cytokine and pro-angiogenesis factor in differentiating malignant from benign exudative effusion.
Elhefny RA; Shaban MM; Shaker OG
Clin Respir J; 2017 Jan; 11(1):49-57. PubMed ID: 25832725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
